Recce Pharmaceuticals Ltd (RCE.AX)

Recce Pharmaceuticals Ltd (RCE.AX) — VMCI valuation read

Across 120 indicators, Recce Pharmaceuticals Ltd (RCE.AX) lands at VMCI 33/100. The Healthcare sector median is 50, so the 17-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on RCE.AX in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, RCE.AX trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of -1.0x leaves covenant headroom for RCE.AX on the trailing balance sheet.

RCE.AX rose 2.5% over the trailing 7 days, with a -8.6% read on a 30-day basis.